The global colorectal cancer therapeutics market size attained a value of USD 14.80 billion in 2022 driven by robust healthcare infrastructure, increased treatment rates, inflated pharmaceutical prices, launch of new medicinal products. The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2023-2031 to attain a value of USD 25.87 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In June 2022, a study was published in The New England Journal of Medicine, which discovered that immune checkpoint inhibitor medication might be particularly beneficial in persons with a specific kind of rectal cancer. It may be sufficiently effective in patients with this type of cancer to avoid the need for additional treatments like surgery.
Participants in the trial had a very particular type of rectal cancer classified as mismatch repair-deficient and locally advanced rectal cancer. This form of cancer could be adequately treated with immunotherapy.
An immune checkpoint inhibitor known as a PD-1 inhibitor was utilised by the researchers, which would prevent cancer cells from destroying the immune system. The study comprised 14 adults with mismatch repair-deficient rectal cancer in stage 2 or stage 3. Dostarlimab, a PD-1 inhibitor, was administered intravenously every three weeks for a period of six months to participants. The participants favourably received this treatment.
By the end of the experiment, none of them required chemoradiotherapy or additional ssurgery, and none of the participants had any signs of tumours. Participants have now completed at least six months of follow-up. Such discoveries are expected to aid the colorectal cancer therapeutics market growth.
In November 2021, Natco Pharma introduced a unique fixed-dose combination of Trifluridine and Tipiracil. This combination is used for the treatment of advanced cancer, especially colorectal and gastric cancer. The medicine was first offered by Natco in a bottle of 20 tablets under the brand name Tipanat. In order to treat advanced colorectal and gastric cancer, a unique antineoplastic nucleoside analogue called Tipanat is used.
Around 1,25,000 new cancer cases are reported annually in India. Tipanat is important in extending survival and maintaining the quality of life in the final stages of treatment, which is an unmet medical need at the moment.
In September 2021, a non-profit cancer research initiative called Count Me In, invited all the patients with colorectal cancer across the United States and Canada. This included patients who were either suffering or have recovered and became cancer-free. They were invited to participate in its research and help drive discoveries related to this disease.
A better understanding of the disease and improved treatments for colorectal cancer would be made possible by the de-identified data collected from the patients who had participated in the project. Thus, increasing research activities by major companies will likely increase the colorectal cancer therapeutics market share.
Colorectal cancer, also referred to as rectal cancer, colon cancer, or bowel cancer, is brought on by the development of cancerous cells in the colon or rectum, which are parts of the large intestine. These cells can expand to other human organs and often act in a malignant manner. Blood in the stools, weight loss, altered bowel habits, and fatigue are the few symptoms of colorectal cancer.
The global market for colorectal cancer therapeutics has a good prospect due to the accessibility of treatment choices and the development of more tailored medications.
The rising consumer acceptance of cutting-edge treatments, including Stivarga (regorafenib), Erbitux (cetuximab), and Avastin (bevacizumab) are expected to aid the colorectal cancer therapeutics market development.
The major market participants would progress and introduce novel therapies, clinical trials, and other studies, which will have a favourable effect on the market.
The colorectal cancer therapeutics market forecast is likely to see a rise in research and development activities, along with a better understanding of colorectal malignancies and associated symptoms.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
High development costs for oncology drugs could slow the expansion of the colorectal cancer therapeutics market because consumers would not be able to afford them. Additionally, because of the unpredictability and regional variation in the approval, clinical acceptance, and inclusion of costly new pharmaceuticals, it is difficult for insurance companies to appropriately calculate policy premiums due to the skyrocketing drug prices.
Throughout the forecast period, various side effects of drugs are anticipated to restrain the colorectal cancer therapeutics market demand. For instance, chemotherapy medication specifically targets rapidly dividing cells, which makes them significantly effective against cancer cells. However, other cells in the body also keep getting divided rapidly, including those in hair follicles and the lining of the mouth and intestines. Chemotherapy can also impact these cells, which may have negative side effects.
Various stringent guidelines for the approval of new treatments, such as FDA approvals, may hamper the market growth globally.
Based on therapy, the market is categorised into immunotherapy, targeted therapy, and chemotherapy, among others. The market forâ¯colorectal cancer therapeutics, based on cancer type, can be segmented into colorectal adenocarcinoma and gastrointestinal carcinoid tumours, among others. The several distribution channels of the market are retail pharmacies, hospital pharmacies, and online channels, among others. The regional markets for the colorectal cancer therapeutics can be divided into Europe, North America, the Asia Pacific, the Middle East and Africa and Latin America.
The analysis of the major players of the global colorectal cancer therapeutics market is examined in a nutshell through this report. Apart from this, this report also covers the competitive landscape and newest developments like mergers, expansion plans, acquisitions and investments.
Due to its sensitivity targeting cancer cells while minimising harm to off-target cells, targeted therapy is favoured. It consists of toxin delivery agents, angiogenesis inhibitors, apoptosis inducers, hormone treatments, and gene expression modulators.
The frequently recommended cancer treatment is chemotherapy. It employs specific medications to eradicate cancer cells or prevent their growth and spread to other bodily regions. Thus, chemotherapy is expected to act as one of the major colorectal cancer therapeutics market drivers.
The use of drugs in immunotherapy aids the immune system of a patient to identify and eliminate cancer cells. It helps individuals suffering from advanced colorectal cancer. Immunotherapy has also demonstrated promising efficacies, along with good tolerance in gastrointestinal (GI)-related cancers, such as gastro-oesophageal cancer and hepatocellular carcinoma.
Colorectal adenocarcinoma is a cancer that occurs in the large intestine, which is made of rectum and colon and is referred to as colorectal. Adenocarcinomas comprise of most of colorectal cancers. Although they seldom affect the colon, these tumours begin in the muscles of the digestive tract. Although many of them do develop into cancer, they can initially be benign (non-cancerous).
Gastrointestinal carcinoid tumours are a form of cancer that can be developed in the GI tract. They are most frequently found in appendix, small intestine, and rectum. Oncogenes or tumour suppressor genes frequently undergo random changes (mutations) that result in carcinoid tumours.
The growth of the hospital segment can be attributed to the growing number of patients visiting hospitals for cancer diagnosis and treatment and the favourable reimbursement scenario, especially in the developed markets.
Retail pharmacies are expanding due to the growing instances of prescriptions re-fillings. Also, retail pharmacies are able to provide more facilities efficiently.
Due to the rising popularity of online pharmacy services, which are becoming more and more popular due to their simplicity and convenience, the online segment is anticipated to experience substantial growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Due to the increasing prevalence of colorectal cancer, growing geriatric population, and strong healthcare infrastructure in the region, North America is anticipated to dominate the market for colorectal cancer therapeutics. Due to the growing prevalence of colorectal cancer, increased treatment rates, inflated pharmaceutical prices, and the availability of advanced treatments in the country, the United States is predicted to control the majority of the market in North America.
By 2030, colorectal cancer will surpass lung cancer as the leading cause of cancer mortality in those between the ages of 20 and 49. It is among the top reasons of death in the United States. According to a National Library of Medicine publication, 0.16 million additional CRC cases are anticipated in the United States in 2020 and will total 0.21 million by 2040.
According to the colorectal cancer therapeutics market research, the demand for colorectal cancer therapies is likely to rise in North America, therefore increasing the market demand globally.
On the other hand, the market in the Asia Pacific region is expected to witness a significant growth rate in the forecast period owing to the availability and accessibility of effective treatment options, increasing disposable incomes, unmet clinical needs of patients, and increasing population in India and China. China is anticipated to have a 64 percent increase in colorectal cancer cases from 0.56 million in 2020 to 0.91 million in 2040.
In addition, Japan is expected to grow rapidly relative to other important markets. Japan is expected to experience 1,48,500 new cases of CRC, 60,000 CRC deaths, and 0.16 million incident cases during the next 20 years. Therefore, the growing cases of cancer are improving the global colorectal cancer therapeutics market value.
Genentech, Inc. is a biotechnology company committed to pioneering research to find and create treatments for people with life-threatening diseases. The first cancer targeted antibody and the first treatment for primary progressive multiple sclerosis are the two of its ground-breaking discoveries.
Eli Lilly and Company is a pharmaceutical manufacturing company. The company is involved in the global research, development, production, marketing, and sales of pharmaceutical goods. Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio are some of its oncology products.
Bayer AG is a life science company working on agriculture and healthcare industries. Bayer currently markets treatments for prostate, colorectal, follicular lymphoma, kidney, liver, and thyroid cancers and a precision treatment for NTRK fusions, which are found in more than 25 solid tumour types, including paediatrics cancers.
Amgen Inc. is one of the global biotechnology firms. It focuses on six therapeutic fields: inflammation, nephrology, neurology, cancer, and cardiovascular disease. The majority of Amgen's medications treat conditions for which there are few effective treatments, or they offer an effective alternative to those that are currently on the market.
F. Hoffmann-La Roche Ltd. (Roche) is a biotechnology corporation which creates medications and diagnostic tools to combat serious illnesses. For cancer treatment and other autoimmune illnesses, it offers medications.
Roche has been working on drugs that will transform oncology care. The company is investing more money than ever to provide individuals with cancer with individualised immunotherapy. These growing investments are acting as colorectal cancer therapeutics market trends.
Sanofi SA is a France-based healthcare organisation. The company focuses on patient needs and works to research, manufacture, and sell therapeutic solutions. Pharmaceuticals, vaccines and consumer healthcare (CHC), make up its three operating segments. The medications cover immunology, diabetes, cardiology, oncology, rare disorders, multiple sclerosis/neurology, and oncology.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Therapy||
|Breakup by Cancer Type||
|Breakup by Route of Administration||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Colorectal Cancer Overview
3.1 Guidelines and Stages
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Colorectal Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Colorectal Cancer Epidemiology (2016-2031)
5.3 Europe Colorectal Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Colorectal Cancer Epidemiology (2016-2031)
5.5 Latin America Colorectal Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Colorectal Cancer Epidemiology (2016-2031)
6 Global Colorectal Cancer Therapeutics Market Overview
6.1 Global Colorectal Cancer Therapeutics Market Historical Value (2016-2022)
6.2 Global Colorectal Cancer Therapeutics Market Forecast Value (2023-2031)
7 Global Colorectal Cancer Therapeutics Market Landscape
7.1 Colorectal Cancer Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Colorectal Cancer Therapeutics: Product Landscape
7.2.1 Analysis by Therapy type
7.2.2 Analysis by Cancer Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
8 Colorectal Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Colorectal Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Colorectal Cancer Therapeutics Market Segmentation
11.1 Global Colorectal Cancer Therapeutics Market by Therapy
11.1.1 Market Overview
11.1.2 Targeted Therapy
11.2 Global Colorectal Cancer Therapeutics Market by Cancer Type
11.2.1 Market Overview
11.2.2 Colorectal Adenocarcinoma
11.2.3 Gastrointestinal Carcinoid Tumors
11.3 Global Colorectal Cancer Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.4 Global Colorectal Cancer Therapeutics Market by End User
11.4.1 Market Overview
11.4.4 Specialty Clinics
11.5 Global Colorectal Cancer Therapeutics Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Colorectal Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
13 Europe Colorectal Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
14 Asia Pacific Colorectal Cancer Therapeutics Market
14.1 Market Share by Country
15 Latin America Colorectal Cancer Therapeutics Market
15.1 Market Share by Country
16 Middle East and Africa Colorectal Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.5 South Africa
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Genentech, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.2 Eli Lilly and Company
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.3 Bayer AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.5 F. Hoffmann-La Roche Ltd.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.6 Pfizer Inc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.8 Accord Healthcare
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.9 Alkem Labs Ltd
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.10 Bausch Health Companies Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.11 Hill Dermaceuticals, Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.12 Bristol-Myers Squibb Company
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.13 Fresenius Kabi USA
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.14 Sagent Pharmaceuticals, Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
24 Colorectal Cancer Therapeutics - Distribution Model (Additional Insight)
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
In 2022, the global market for colorectal cancer therapeutics reached a value of USD 14.80 billion.
The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2023-2031 to reach a value of USD 25.87 billion by 2031.
The major drivers of the colorectal cancer therapeutics market include the robust healthcare infrastructure, increased treatment rates, inflated pharmaceutical prices, launch of new medicinal products. Growing clinical trials, availability and accessibility of effective treatment options, government initiatives, and emergence of more front-line therapies are also aiding the market growth.
The rising incidence of colorectal cancer and increasing geriatric population are the key industry trends propelling the growth of the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on therapy, the market is divided into targeted therapy, immunotherapy, and chemotherapy, among others.
The market for colorectal cancer therapeutics, based on cancer type, can be segmented into colorectal adenocarcinoma and gastrointestinal carcinoid tumours, among others.
The several distribution channels of the market are hospital pharmacies, retail pharmacies, and online, among others.
Targeted drugs function unlike the chemotherapy (chemo) drugs. They sometimes function when chemo medicines do not, and they generally have different adverse effects. They can be taken in conjunction with chemo or on its own if chemo is no longer effective.
Surgery is the most effective treatment for colorectal cancer. Other therapies, such as radiation therapy and chemotherapy, may be suggested as well.
The major players in the colorectal cancer therapeutics market are Genentech, Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., F. Hoffmann-La Roche Ltd., and Sanofi SA, among others.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.